Gelteq Enters 3-Year Sales Agreement with Mana, Projecting $1.3M Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: Globenewswire
- Market Expansion Opportunity: Gelteq has signed a three-year sales agreement with Shenzhen Mana Health Management Co. Ltd., projecting a minimum revenue of approximately $1.3 million during the term, thereby accelerating its entry into China's rapidly growing nutritional product market.
- Leveraging Channel Advantages: Mana's strong digital presence and offline retail channels will effectively promote Gelteq's sugar-lowering nutritional formulations, utilizing its existing platform to reach a broader consumer base across the country.
- Product Portfolio Enrichment: The agreement not only covers sugar-lowering products but also paves the way for introducing additional nutritional products incorporating Gelteq's proprietary technology, further enhancing the company's product diversity.
- Deepening Strategic Partnerships: Gelteq CEO Nathan Givoni stated that this collaboration represents a significant milestone in the Chinese market, aiming to generate predictable revenue through long-term commitments with distributors, thereby strengthening its strategic position in the global nutritional products market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GELS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GELS
About GELS
Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
- Bioavailability Improvement: Gelteq Ltd's oral gel delivery platform achieved over a 22% increase in bioavailability compared to an FDA-approved oil-based product in preclinical trials, indicating significant technological advantages that could enhance market acceptance and drive future sales growth.
- Stock Surge: Following this positive announcement, Gelteq's shares surged 50.1% in pre-market trading to $1.25, reflecting strong investor confidence in the new technology and its market potential.
- Enhanced Market Competitiveness: By improving product bioavailability, Gelteq not only meets the growing consumer demand but also positions itself more favorably in the competitive pharmaceutical market, potentially driving the company's long-term strategic development.
- Increased Investor Interest: With Gelteq's technological advancements and stock price increase, market attention on its future performance has significantly risen, likely attracting more investors and partners, thereby facilitating the company's capital operations and business expansion.
Continue Reading
U.S. Stock Futures Decline as CPI Rises 2.7% Year Over Year
- CPI Data Release: The U.S. Consumer Price Index rose 2.7% year over year in December, matching both the previous reading and economists' estimates, indicating persistent inflationary pressures that could influence Federal Reserve policy decisions.
- Weak Market Performance: The Dow Jones fell by 0.15%, while the S&P 500 and Nasdaq 100 declined by 0.16% each, reflecting investor concerns over future economic growth, which may lead to further deterioration in market sentiment.
- Bond Yield Dynamics: The 10-year Treasury bond yielded 4.17%, while the two-year bond yielded 3.52%, indicating market expectations for unchanged interest rates, which could impact investors' asset allocation strategies.
- Analyst Outlook: Professor Jeremy Siegel anticipates robust economic growth in 2026, emphasizing that small-cap and non-tech cyclical stocks will benefit from expected Federal Reserve rate cuts, advising investors to broaden their portfolios to capture opportunities in global markets.
Continue Reading